It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...
This season will be the first time in Ontario that nirsevimab (sold under the brand name Beyfortus) is used to protect babies ...
Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...
Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...
In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million) in 2023. While cross-trial comparisons carry inherent ...
Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest ...
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus ...
Starting Nov. 4, all babies born in 2024 able to get the Beyfortus immunization for free through their public health unit, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback